1.90 - 2.15
0.48 - 2.54
9.88M / 3.06M (Avg.)
-0.59 | -3.40
Reveals whether the business's core operations generate sufficient cash to cover expenses, fund growth, and return capital to shareholders. Sustainable free cash flow is often a key indicator of long-term value creation.
0.01
OCF/share of 0.01 while Drug Manufacturers - Specialty & Generic median is zero. Walter Schloss would see if modest cash generation can build a stronger lead.
0.00
Positive FCF/share while Drug Manufacturers - Specialty & Generic median is negative. Peter Lynch might see a strong edge over peers.
95.59%
Capex/OCF ratio of 95.59% while the Drug Manufacturers - Specialty & Generic median is zero. Walter Schloss would confirm if minimal reinvestment is enough for advantage.
0.13
Ratio below 0.5x Drug Manufacturers - Specialty & Generic median of 0.41. Jim Chanos would suspect significant earnings quality problems.
4.31%
OCF-to-sales ratio of 4.31% while Drug Manufacturers - Specialty & Generic is zero. Walter Schloss might see a modest advantage in actually generating some cash.